Camonsertib

Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity[1].

Product Specifications

CAS Number

[2417489-10-0]

Product Name Alternative

RP-3500; ATR inhibitor 4

UNSPSC

12352005

Target

ATM/ATR; mTOR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/camonsertib.html

Purity

99.99

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O[C@@]1(C[C@H]2O[C@H](CC2)C1)C3=C4C(N(C5=NNC=C5)N=C4)=NC(N6[C@@H](COCC6)C)=C3

Molecular Formula

C21H26N6O3

Molecular Weight

410.47

References & Citations

[1]Anne Roulston, et al. RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. Mol Cancer Ther